A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Clinical trial NCT06126224 · RECRUITING
Trial details
- NCT number
- NCT06126224
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-28
- Primary completion
- 2026-12-09
- Enrollment
- 500
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.